NcXHF

THE SPECTRUM OF NEUROENDOCRINE TUMORS
assessment of Ki67 labeling index in well-differentiated neuroendocrine
tumors metastatic to the liver: implications for prognostic stratifıcation.
Am J Surg Pathol. 2011;35:853-860.
23. Khan MS, Luong TV, Watkins J, et al. A comparison of Ki-67 and mitotic
count as prognostic markers for metastatic pancreatic and midgut
neuroendocrine neoplasms. Br J Cancer. 2013;108:1838-1845.
24. McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated
pancreatic neuroendocrine tumors is improved by the inclusion of
both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;
37:1671-1677.
25. Singh S, Hallet J, Rowsell C, et al. Variability of Ki67 labeling index in
multiple neuroendocrine tumors specimens over the course of the disease.
Eur J Surg Oncol. 2014;40:1517-1522.
26. Klimstra DS. Pathology reporting of neuroendocrine tumors: essential
elements for accurate diagnosis, classifıcation, and staging. Semin Oncol.
2013;40:23-36.
27. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX. MEN1, and mTOR pathway
genes are frequently altered in pancreatic neuroendocrine tumors.
Science. 2011;331:1199-1203.
28. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine
carcinomas of the pancreas are genetically similar and
distinct from well-differentiated pancreatic neuroendocrine tumors.
Am J Surg Pathol. 2012;36:173-184.
29. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA
methyltransferase defıciency and response to temozolomide-based
therapy in patients with neuroendocrine tumors. Clin Cancer Res.
2009;15:338-345.
30. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic
neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
31. Han X, Ji Y, Zhao J, et al. Expression of PTEN and mTOR in pancreatic
neuroendocrine tumors. Tumour Biol. 2013;34:2871-2879.
32. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of
the lung with proposed criteria for large-cell neuroendocrine carcinoma.
an ultrastructural, immunohistochemical, and flow cytometric
study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
33. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary
neuroendocrine tumors with clarifıcation of criteria for atypical
carcinoid and its separation from typical carcinoid. Am J Surg Pathol.
1998;22:934-944.
34. Skov BG, Krasnik M, Lantuejoul S, et al. Reclassifıcation of neuroendocrine
tumors improves the separation of carcinoids and the prediction
of survival. J Thorac Oncol. 2008;3:1410-1415.
35. Rindi G, Klersy C, Inzani F, et al. Grading the neuroendocrine tumors
of the lung: an evidence-based proposal. Endocr Relat Cancer. 2013;21:
1-16.
36. Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung
neuroendocrine. Thorac Surg Clin. 2014;24:257-266.
37. Oba H, Nishida K, Takeuchi S, et al. Diffuse idiopathic pulmonary
neuroendocrine cell hyperplasia with a central and peripheral carcinoid
and multiple tumorlets: a case report emphasizing the role of neuropeptide
hormones and human gonadotropin-alpha. Endocr Pathol.
2013;24:220-228.
38. Yokota J, Akiyama T, Fung YK, et al. Altered expression of the retinoblastoma
(RB) gene in small-cell carcinoma of the lung. Oncogene.
1988;3:471-475.
39. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help
characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:
798-809.
40. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent mutations in
chromatin-remodelling genes in pulmonary carcinoids. Nat Commun.
2014;5:3518.
41. Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classifıcation
of prostate cancer with neuroendocrine differentiation. Am J
Surg Pathol. 2014;38:756-767.
42. Tamas EF, Epstein JI. Prognostic signifıcance of paneth cell-like neuroendocrine
differentiation in adenocarcinoma of the prostate. Am J
Surg Pathol. 2006;30:980-985.
43. Nadal R, Schweizer M, Kryvenko ON, et al. Small cell carcinoma of the
prostate. Nat Rev Urol. 2014;11:213-219.
44. Wang L, Davidson DD, Montironi R, et al. Small cell carcinoma of the
prostate: molecular basis and clinical implications. Histol Histopathol.
Epub 2014 Nov 10.
45. Grodick MA, Muren NB, Barton JK. DNA charge transport within the
cell. Biochemistry. 2015;3:962-973.
46. Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic
small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20:890-903.
47. Beltran H, Rickman DS, Park K, et al. Molecular characterization of
neuroendocrine prostate cancer and identifıcation of new drug targets.
Cancer Discov. 2011;1:487-495.
48. Berman-Booty LD, Knudsen KE. Models of neuroendocrine prostate
cancer. Endocr Relat Cancer. 2015;22:R33-R49.
49. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb
defıciency in a conditional mouse model for metastatic prostate cancer.
Cancer Res. 2006;66:7889-7898.
50. Tzelepi V, Zhang J, Lu JF, et al. Modeling a lethal prostate cancer variant
with small-cell carcinoma features. Clin Cancer Res. 2012;18:666-677.
51. Lapuk AV, Wu C, Wyatt AW, et al. From sequence to molecular pathology,
and a mechanism driving the neuroendocrine phenotype in
prostate cancer. J Pathol. 2012;227:286-297.
52. Logothetis CJ, Gallick GE, Maity SN, et al. Molecular classifıcation of
prostate cancer progression: foundation for marker-driven treatment
of prostate cancer. Cancer Discov. 2013;3:849-861.
53. Lin D, Dong X, Wang K, et al. Identifıcation of DEK as a potential
therapeutic target for neuroendocrine prostate cancer. Oncotarget.
2015;6:1806-1820.
54. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and
MYCN gene amplifıcations are harbingers of lethal treatment-related
neuroendocrine prostate cancer. Neoplasia. 2013;15:1-10.
55. Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG
rearrangement in prostatic small cell carcinoma detected by fluorescence
in situ hybridization: the superiority of fluorescence in situ hybridization
over ERG immunohistochemistry. Hum Pathol. 2013;44:2227-2233.
56. Castellano D, Grande E, Valle J, et al. Expert consensus for the management
of advanced or metastatic pancreatic neuroendocrine or carcinoid
tumors. Cancer Chemother Pharmacol. Epub 2014 Dec 6.
57. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine
tumors (PNETs): incidence, prognosis, and recent trend toward improved
survival. Ann Oncol. 2008;19:1727-1733.
58. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors
of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36:
933-942.
59. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”:
epidemiology of and prognostic factors for neuroendocrine tumors in
35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
60. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine
tumours. Lancet Oncol. 2008;9:61-72.
61. van Asselt SJ, Brouwers AH, van Dullemen HM, et al. EUS is superior
for detection of pancreatic lesions compared with standard imaging in
patients with multiple endocrine neoplasia type 1. Gastrointest Endosc.
2015;81:159-167.
62. Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients
with nonmetastatic, surgically resected pancreatic neuroendocrine
tumors: an analysis of the AJCC and ENETS staging
classifıcations. Ann Surg. 2012;256:321-325.
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK 101